Cargando…
Targeted Therapy and Immunotherapy for Melanoma in Japan
Melanoma has several clinically and pathologically distinguishable subtypes, which also differ genetically. Mutation patterns vary among different melanoma subtypes, and efficacy of immune-checkpoint inhibitors differs depending on the subtype of melanoma. In spite of the recent revolution of system...
Autores principales: | Namikawa, Kenjiro, Yamazaki, Naoya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6344396/ https://www.ncbi.nlm.nih.gov/pubmed/30675668 http://dx.doi.org/10.1007/s11864-019-0607-8 |
Ejemplares similares
-
Targeted Therapy for Melanomas Without BRAF V600 Mutations
por: Menzer, Christian, et al.
Publicado: (2022) -
Advanced Acral Melanoma Therapies: Current Status and Future Directions
por: Zhang, Yiqun, et al.
Publicado: (2022) -
Neoadjuvant Therapy for Non-melanoma Skin Cancer: Updated Therapeutic Approaches for Basal, Squamous, and Merkel Cell Carcinoma
por: Zelin, Enrico, et al.
Publicado: (2021) -
Autophagy Paradox: Strategizing Treatment Modality in Melanoma
por: Pangilinan, Christian, et al.
Publicado: (2023) -
BRAF Inhibitor Resistance in Melanoma: Mechanisms and Alternative Therapeutic Strategies
por: Zhong, Jingqin, et al.
Publicado: (2022)